Spheroid-based drug screen: considerations and practical approach.

Although used in academicresearch for several decades, 3D culture models have long been regarded expensive, cumbersome and unnecessary in drug development processes.

Technical advances, coupled with recent observations showing that gene expression in 3D is much closer to clinical expression profiles than those seen in 2D, have renewed attention and generated hope in the feasibility of maturing organotypic 3D systems to therapy test platforms with greater power to predict clinical efficacies.

Here we describe a standardized setup for reproducible, easy-handling culture, treatment and routine analysis of multicellular spheroids, the classical 3D culture system resembling many aspects of the pathophysiological situation in human tumor tissue.

We discuss essential conceptual and practical considerations for an adequate establishment and use of spheroid-based drug screening platforms and also provide a list of human carcinoma cell lines, partly on the basis of the NCI-DTP 60-cell line screen, that produce treatable spheroids under identical culture conditions.

In contrast to many other settings with which to achieve similar results, the protocol is particularly useful to be integrated into standardized large-scale drug test routines as it requires a minimum number of defined spheroids and a limited amount of drug.

The estimated time to run the complete screening protocol described herein–including spheroid initiation, drug treatment and determination of the analytical end points (spheroid integrity, and cell survival through the acid phosphatase assay)–is about 170 h. Monitoring of spheroid growth kinetics to determine growth delay and regrowth, respectively, after drug treatment requires long-term culturing >> or =14 d).

KT 5720
B9002-.05 50 µg
EUR 145

KT 5720
B9002-.1 100 µg
EUR 232

KT 5720
B9002-.25 250 µg
EUR 483

KT 5720
B9002-.5 500 µg
EUR 818

PST- KT
PVT11358 2 ug
EUR 370

KT 5823 (PKG kinase inhibitor)
SIH-458-100UG 100 µg
EUR 205
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml).

KT 5823 (PKG kinase inhibitor)
SIH-458-500UG 500 µg
EUR 569
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml).

Plasminogen Receptor (KT) (PLGRKT) Antibody
20-abx318476
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Epothilone B
HY-17029 10mM/1mL
EUR 158

EID1 antibody
70R-17029 50 ul
EUR 435
Description: Rabbit polyclonal EID1 antibody

Rat Chondroitin Sulfate Epitope 3B3(CS3B3 ELISA Kt
GA-E0451RT-48T 48T
EUR 317

Rat Chondroitin Sulfate Epitope 3B3(CS3B3 ELISA Kt
GA-E0451RT-96T 96T
EUR 496

Rat Chondroitin Sulfate Epitope 3B3(CS3B3 ELISA Kt
QY-E11201 96T
EUR 361

Mouse Chondroitin Sulfate Epitope 3B3(CS3B3 ELISA Kt
QY-E20317 96T
EUR 361

Factor XI Antibody Pair
55R-FAC11-KT 5 plates
EUR 745
Description: Factor XI antigen Matched Pair antibody Set for ELISA

Factor IX Antibody Pair
55R-FAC9-KT 5 plates
EUR 760
Description: Factor IX antigen Matched Pair antibody Set for ELISA

Fibrinogen Matched Pair antibody Set
55R-FIBRINO-KT set
EUR 833
Description: Fibrinogen Matched Pair antibody Set for detection of Human Fibrinogen in the research laboratory

Mouse RANKL ELISA Kit
55R-MRANKL-KT 1 kit
EUR 658
Description: ELISA kit for detection of Mouse RANKL in the research laboratory

VWF Antibody Pair
55R-VWF-KT 5 plates
EUR 775
Description: VWF antigen Matched Pair antibody Set for ELISA